Skip to content

SANA Sana Biotechnology Inc

NASDAQ
Health Care
Biotechnology

$2.31

▼ 6.7%

Updated Oct 16, 2:25 PM ET

Report Card

SANA at a glance — five pillars scored 0–100 from real filed financials.

How the 0–100 rating is calculated
Value
—
Growth
—
Profitability
—
Health
44
Dividends
—

Overall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.

Key Metrics

Market Cap

—

P/E

—

Forward P/E (est.)

—

ROE

—

Revenue Growth

—

EPS Growth

—

Profit Margin

—

FCF Yield

—

Debt / Equity

—

ROIC

—

Interest Coverage

—

Current Ratio

1.38x

Dividend Yield

—

Implied Growth (rev. DCF)

—

Rating Score

Not rated

Business Overview

Research

Sana Biotechnology Inc (SANA) is a NASDAQ-listed company in the Biotechnology industry, within the Health Care sector.

Our model hasn't rated SANA yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.

Metrics vs. Sector Range

Where SANA sits versus the Health Care companies we cover.

TTM P/E
——
Forward P/E
——
P/S ratio
——
Revenue growth
——
EPS growth
——
Gross margin
——
Net margin
——
ROE
——

Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How SANA stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.

SANA doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.

P/E vs sector

—

median 26.1x

ROE vs sector

—

median 14.1%

Growth vs sector

—

median 7.6%

Sector rank

—

not rated yet

CompanyP/ERev Gr.Rating
SANAThis stock——Not rated
ABVX——Weak· 35
GMAB20.9x20.7%Favorable· 62
INCY15.7x21.5%Strong· 86
BNTX—-11.8%Weak· 31
MRNA—-30.0%Weak· 17
BIIB25.3x1.2%Neutral· 44
ONC71.9x36.2%Neutral· 48
Health Care median26.1x7.6%52/100

Valuation vs. quality map

sector medianGMABINCYBIIBONCP/E — cheaper ←→ pricierROE — more profitable ↑

The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.

Compare side by side

Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.

Key Risks

Research

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Analyst Ratings

What 15 Wall Street analysts covering SANA recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.

Buy
consensus · score 4.3 / 5 across 15 analysts
Strong Buy 6Buy 7Hold 2Sell 0Strong Sell 0

Latest SEC Filings

SANA's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K

SANA — frequently asked questions

Is SANA a good stock to buy?

We don't give buy or sell advice. Review Sana Biotechnology Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.

Where does SANA's data come from?

Live price data plus the annual financials in Sana Biotechnology Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.

How is the 5-year projection for SANA calculated?

It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.

Is this SANA analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell SANA. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.